An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation.

• Main Authors: Stephanie Traub, Alexandra Nikonova, Alan Carruthers, Rebecca Dunmore, Katherine A Vousden, Leila Gogsadze, Weidong Hao, Qing Zhu, Katie Bernard, Jie Zhu, Michael Dymond, Gary R McLean, Ross P Walton, Nicholas Glanville, Alison Humbles, Musa Khaitov, Ted Wells, Roland Kolbeck, Andrew J Leishman, Matthew A Sleeman, Nathan W Bartlett, Sebastian L Johnston
• Format: Article
• Language: English
• Published: Public Library of Science (PLoS) 2013-01-01
• Series: PLoS Pathogens
• Online Access: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23935498/pdf/?tool=EBI
• ISSN: 1553-7366; 1553-7374

Human rhinoviruses (HRV) cause the majority of common colds and acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Effective therapies are urgently needed, but no licensed treatments or vaccines currently exist. Of the 100 identified serotypes, ∼90% bind domain 1 of human intercellular adhesion molecule-1 (ICAM-1) as their cellular receptor, making this an attractive target for development of therapies; however, ICAM-1 domain 1 is also required for host defence and regulation of cell trafficking, principally via its major ligand LFA-1. Using a mouse anti-human ICAM-1 antibody (14C11) that specifically binds domain 1 of human ICAM-1, we show that 14C11 administered topically or systemically prevented entry of two major groups of rhinoviruses, HRV16 and HRV14, and reduced cellular inflammation, pro-inflammatory cytokine induction and virus load in vivo. 14C11 also reduced cellular inflammation and Th2 cytokine/chemokine production in a model of major group HRV-induced asthma exacerbation. Interestingly, 14C11 did not prevent cell adhesion via human ICAM-1/LFA-1 interactions in vitro, suggesting the epitope targeted by 14C11 was specific for viral entry. Thus a human ICAM-1 domain-1-specific antibody can prevent major group HRV entry and induction of airway inflammation in vivo.